Revisiting mitochondrial diagnostic criteria in the new era of genomics

Type of publication: Diagnosis, Guidelines
Disease: Mitochondrial disease

Authors:

Peter Witters MD, PhD, Ann Saada MD, PhD, Tomas Honzik MD, PhD, Marketa Tesarova PhD, Stephanie Kleinle PhD, Rita Horvath MD, PhD, Amy Goldstein MD, PhD & Eva Morava MD, PhD


Purpose

Diagnosing primary mitochondrial diseases (MDs) is challenging in clinical practice. The mitochondrial disease criteria (MDC) have been developed to quantify the clinical picture and evaluate the probability of an underlying MD and the need for a muscle biopsy. In this new genetic era with next-generation sequencing in routine practice, we aim to validate the diagnostic value of MDC.

Methods

We retrospectively studied MDC in a multicenter cohort of genetically confirmed primary MD patients.

Results

We studied 136 patients (61 male, 91 nuclear DNA (nDNA) mutations). Forty-five patients (33%) had probable MD and 69 (51%) had definite MD according to the MDC. A muscle biopsy was performed in 63 patients (47%). Patients with nDNA mutations versus mitochondrial DNA mutations were younger (6.4 ± 9.7 versus 19.5 ± 17.3 y) and had higher MDC (7.07 ± 1.12/8 versus 5.69 ± 1.94/8). At a cutoff of 6.5/8, the sensitivity to diagnose patients with nDNA mutations is 72.5% with a positive predictive value of 69.5%. In the nDNA mutation group, whole-exome sequencing could diagnose patients with lower scores (MDC (6.84 ± 1.51/8) compared to Sanger sequencing MDC (7.44 ± 1.13/8, P = 0.025)). Moreover 7/8 patients diagnosed with possible MD by MDC were diagnosed by whole-exome sequencing.

Conclusion

MDC remain very useful in the clinical diagnosis of MD, in interpreting whole-exome results and deciding on the need for performing muscle biopsy.


Published: 26 October 2017
Journal: Genetics in Medicine, volume 20, issue 4, pages 444–451

Link: doi.org/10.1038/gim.2017.125

This publication is recommended by the Mitochondrial Diseases Working Group group.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern